GlassScriptPhysician profile
Dana D Morrel
NPI 1417918954
$13,705.47
in general payments reported to CMS, 2019-2025
48 companies · $2,747 in 2025
The $2,747 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $1,003 · 2021: $184 · 2022: $2,072 · 2023: $2,875 · 2024: $2,519 · 2025: $2,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,035 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,035.40 |
| Education | $104.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,544.73 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,393.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,303.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $957.40 | 2019-2025 | |
| Lilly USA, LLC | $917.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $868.59 | 2019-2025 | Otezla, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $702.40 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $516.61 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.20 | 2019-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $395.07 | 2023-2025 | Rexulti |
| Abbott Laboratories | $347.17 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $335.34 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $319.43 | 2019-2023 | Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.91 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $296.38 | 2019-2025 | Veozah |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Morrel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.